ArticleDrug design, development and therapy2026
Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody?
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpreting Rituximab Response in Seronegative Membranous Nephropathy [Response to Letter].Drug design, development and therapy · 2026Article
- Interpreting Rituximab Response in Seronegative Membranous Nephropathy [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rituximab (RTX) induces apoptosis in B cells expressing CD20, the efficacy in idiopathic membranous nephropathy (IMN) with seronegative anti-M-type phospholipase A2 receptor (PLA2R) antibody remains unclear. Methods: This multicenter retrospective study enrolled 111 adult patients with biopsy-proven, medium-to-high-risk IMN, whose serum anti-PLA2R antibodies test results were negative (SAb-). All patients received RTX and non-RTX (tacrolimus or cyclophosphamide) therapy. Subsequently, based on glomerular PLA2R antigen results, they divided into glomerular PLA2R positive (GAg+) and glomerular PLA2R negative (GAg-) groups. Compared the remission rate at 15 months between different treatment groups. Results: Of the 111 seronegative patients, 36 were assigned to the RTX group and 75 to the non-RTX group. Among the 76 GAg+ patients, 21 were in the RTX group and 45 in the non-RTX group. Kaplan-Meier analysis demonstrated that the complete remission rate was significantly higher in the non-RTX group than in the RTX groups at 15 months, both in total and SAb-/GAg+ cohort ( Conclusion: For seronegative anti-PLA2R antibodies patients, non-RTX immunosuppressive therapy might offer greater benefit for proteinuria remission compared to RTX in short-term, even if their glomeruli are positive for PLA2R antigen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.